日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Genetic Basis of Multiple Antibiotic Resistance of Pathogenic Escherichia coli Strains Isolated from Livestock Complexes in Krasnodar Krai, Russia

俄罗斯克拉斯诺达尔边疆区畜牧场分离的致病性大肠杆菌菌株多重抗生素耐药性的遗传基础

Tishchenko, Alexander; Shumkov, Mikhail; Kazakova, Elizaveta; Tarasova, Irina; Karpov, Dmitry; Kopyltsov, Sergey; Goncharenko, Anna

Maintenance Therapy With Avelumab for Patients With Metastatic Urothelial Carcinoma: A Real-World, Ambispective RAVE-Bladder Study

阿维鲁单抗维持治疗转移性尿路上皮癌患者:一项真实世界、回顾性研究(RAVE-Bladder 研究)

Tsimafeyeu, Ilya; Gridneva, Yana; Sultanbaev, Alexander; Anzhiganova, Yulia; Gluzman, Mark; Mochalova, Anastasia; Shkurat, Alexey; Israelyan, Edgar; Parsadanova, Elvira; Murzina, Yulia; Ivanov, Aleksei; Kalpinskiy, Alexey; Stativko, Olesia; Petkau, Vladislav; Karabina, Elena; Kеln, Artyom; Tovbik, Natalya; Safina, Sufia; Turganova, Maria; Kopyltsov, Evgeny; Bragina, Varvara; Novikova, Olga; Lebedinets, Andrei; Vodolazskiy, Vladislav; Rumyantsev, Alexey; Zukov, Ruslan; Pokataev, Ilya; Orlova, Rashida; Volkova, Maria

Draft genome of Lactobacillus amylovorus KSAU with probiotic potential isolated from the gastrointestinal tract of industrial pigs

从工业猪胃肠道中分离得到的具有益生菌潜力的乳酸杆菌KSAU的基因组草图

Lysenko, Yuri A; Milovanov, Alexander V; Kopyltsov, Sergey V; Gahurová, Dominika; Elisiutikova, Anastasia V

Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study

仑伐替尼联合帕博利珠单抗对比舒尼替尼在晚期肾细胞癌一线治疗中的应用:III 期临床研究 CLEAR 的最终预设总生存期分析

Robert J Motzer, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Grünwald, Thomas E Hutson, Boris Alekseev, Sun Young Rha, Jaime Merchan, Jeffrey C Goh, Aly-Khan A Lalani, Ugo De Giorgi, Bohuslav Melichar, Sung-Hoo Hong, Howard Gurney, María José Méndez-Vidal, Evgeny Kopyltsov, Sergei Tjulandin,

Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial

来自 III 期 ARANOTE 试验的达罗鲁胺联合雄激素剥夺疗法治疗转移性激素敏感性前列腺癌患者

Saad, Fred; Vjaters, Egils; Shore, Neal; Olmos, David; Xing, Nianzeng; Pereira de Santana Gomes, Andrea Juliana; Cesar de Andrade Mota, Augusto; Salman, Pamela; Jievaltas, Mindaugas; Ulys, Albertas; Jakubovskis, Maris; Kopyltsov, Evgeny; Han, Weiqing; Nevalaita, Liina; Testa, Isabella; Le Berre, Marie-Aude; Kuss, Iris; Haresh, Kunhi Parambath

Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study

晚期肾细胞癌患者接受乐伐替尼联合帕博利珠单抗治疗与舒尼替尼治疗相比,根据反应深度和疗效评估的生存率:CLEAR III期随机研究分析

Grünwald, Viktor; Powles, Thomas; Kopyltsov, Evgeny; Kozlov, Vadim; Alonso-Gordoa, Teresa; Eto, Masatoshi; Hutson, Thomas; Motzer, Robert; Winquist, Eric; Maroto, Pablo; Keam, Bhumsuk; Procopio, Giuseppe; Wong, Shirley; Melichar, Bohuslav; Rolland, Frederic; Oya, Mototsugu; Rodriguez-Lopez, Karla; Saito, Kenichi; McKenzie, Jodi; Porta, Camillo

Treatment of Low-grade Intermediate-risk Nonmuscle-invasive Bladder Cancer With UGN-102 ± Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS)

UGN-102 ± 经尿道膀胱肿瘤切除术治疗低级别中危非肌层浸润性膀胱癌与经尿道膀胱肿瘤切除术单药治疗的比较:一项随机、对照、3期试验(ATLAS)

Prasad, Sandip M; Huang, William C; Shore, Neal D; Hu, Brian; Bjurlin, Marc; Brown, Gordon; Genov, Pencho; Shishkov, Dimitar; Khuskivadze, Alexandre; Ganev, Tosho; Marchev, Dobri; Orlov, Igor; Kopyltsov, Evgeny; Zubarev, Vadim; Nosov, Alexander; Komlev, Dmitrii; Burger, Brent; Raju, Sunil; Meads, Andrew; Schoenberg, Mark

Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms

CLEAR III期研究在晚期肾细胞癌患者中的应用:乐伐替尼联合帕博利珠单抗组和舒尼替尼组的亚组疗效

Grünwald, Viktor; Powles, Thomas; Eto, Masatoshi; Kopyltsov, Evgeny; Rha, Sun Young; Porta, Camillo; Motzer, Robert; Hutson, Thomas E; Méndez-Vidal, María José; Hong, Sung-Hoo; Winquist, Eric; Goh, Jeffrey C; Maroto, Pablo; Buchler, Tomas; Takagi, Toshio; Burgents, Joseph E; Perini, Rodolfo; He, Cixin; Okpara, Chinyere E; McKenzie, Jodi; Choueiri, Toni K

Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms

更正:CLEAR III期研究(晚期肾细胞癌患者):乐伐替尼联合帕博利珠单抗组和舒尼替尼组的亚组结果

Grünwald, Viktor; Powles, Thomas; Eto, Masatoshi; Kopyltsov, Evgeny; Rha, Sun Young; Porta, Camillo; Motzer, Robert; Hutson, Thomas E; Méndez-Vidal, María José; Hong, Sung-Hoo; Winquist, Eric; Goh, Jeffrey C; Maroto, Pablo; Buchler, Tomas; Takagi, Toshio; Burgents, Joseph E; Perini, Rodolfo; He, Cixin; Okpara, Chinyere E; McKenzie, Jodi; Choueiri, Toni K

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer

达罗鲁胺与转移性激素敏感性前列腺癌的生存率

Smith, Matthew R; Hussain, Maha; Saad, Fred; Fizazi, Karim; Sternberg, Cora N; Crawford, E David; Kopyltsov, Evgeny; Park, Chandler H; Alekseev, Boris; Montesa-Pino, Álvaro; Ye, Dingwei; Parnis, Francis; Cruz, Felipe; Tammela, Teuvo L J; Suzuki, Hiroyoshi; Utriainen, Tapio; Fu, Cheng; Uemura, Motohide; Méndez-Vidal, María J; Maughan, Benjamin L; Joensuu, Heikki; Thiele, Silke; Li, Rui; Kuss, Iris; Tombal, Bertrand